title: [Use of Omniscan (gadodiamide) in magnetic resonance studies of the central nervous system (results of a multicenter study)].
abstract: The aim the study: was to conduct first in Russia multicenter trial of gadodiamide in brain and spine MRI in adult patients. Open noncomparative multicenter (5 clinical centres) study. Brain and spine MRI was performed in 190 adult patients with signs of CNS disorders. Field strength of MR imagers was 0.04-1.5 T. Gadodiamide ("Omniscan", "Nycomed Imaging", Nycomed) was injected IV in dose 0.1 mmol/ml. Contrast enhancement was obtained in 74% cases. Gadodiamide allowed to detect more new lesions, better differentiate borders and internal structure of lesions, to differentiate them from oedema and surrounding structures. Contrast-enhanced MR images were superior to non-enhanced T1 and T2-weighted images and to CT images (before and after contrast enhancement). Use of gadodiamide increased confidence in diagnoses in 90.4% cases, changed the diagnosis in 30.3% cases. The general number of adverse events was 2.6%. Adverse reactions to gadodiamide were seen in 1.6%; all of them were of mild intensity without need for therapy. Gadodiamide is an effective and safe nonionic paramagnetic contrast media for brain and spine MRI in adult patients.
authors.forename: V E
authors.initials: VE
authors.lastname: Sinitsyn
authors.forename: V N
authors.initials: VN
authors.lastname: Kornienko
authors.forename: V G
authors.initials: VG
authors.lastname: Nikitin
authors.forename: I N
authors.initials: IN
authors.lastname: Pronin
authors.forename: S K
authors.initials: SK
authors.lastname: Ternovoĭ
authors.forename: L A
authors.initials: LA
authors.lastname: Tiutin
authors.forename: M G
authors.initials: MG
authors.lastname: Iakobson
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001932:Brain Neoplasms / Q000175:diagnosis; D002493:Central Nervous System Diseases / Q000175:diagnosis*; D003287:Contrast Media / Q000008:administration & dosage / Q000009:adverse effects; D003937:Diagnosis, Differential; D005069:Evaluation Studies as Topic; D005260:Female; D005290:Ferric Compounds; D005682:Gadolinium / Q000008:administration & dosage / Q000009:adverse effects; D019786:Gadolinium DTPA; D006801:Humans; D007275:Injections, Intravenous; D007501:Iron; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D009942:Organometallic Compounds / Q000008:administration & dosage / Q000009:adverse effects; D010087:Oxides; D004369:Pentetic Acid / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D013120:Spinal Cord Neoplasms / Q000175:diagnosis
chemical_list: D003287:Contrast Media; D005290:Ferric Compounds; D009942:Organometallic Compounds; D010087:Oxides; C069727:Sonazoid; D004369:Pentetic Acid; C064925:gadodiamide; D005682:Gadolinium; D007501:Iron; D019786:Gadolinium DTPA
vernacular_title: Primenenie "Omniskana" (gadodiamida) pri magnitnom rezonansnom issledovanii tsentral'noĭ nervnoĭ sistemy (rezul'taty mnogotsentrovogo issledovaniia).